High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations

This phase 2 trial assessed high-dose IV ascorbic acid in TET2 mutant clonal cytopenia. Eight of 10 patients were eligible for response assessment, with no responses at week 20 by International Working Group Myelodysplasia Syndromes/Neoplasms criteria. This trial was registered at www.clinicaltrials...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2024-12, Vol.144 (23), p.2456-2461
Main Authors: Xie, Zhuoer, Fernandez, Jenna, Lasho, Terra, Finke, Christy, Amundson, Michelle, McCullough, Kristen B., LaPlant, Betsy R., Mangaonkar, Abhishek A., Gangat, Naseema, Reichard, Kaaren K., Elliott, Michelle, Witzig, Thomas E., Patnaik, Mrinal M.
Format: Article
Language:English
Subjects:
Adult
Aged
Ascorbic Acid - administration & dosage
Ascorbic Acid - therapeutic use
Dioxygenases
DNA-Binding Proteins - genetics
Female
Humans
Male
Middle Aged
Mutation
Myelodysplastic Syndromes - drug therapy
Myelodysplastic Syndromes - genetics
Proto-Oncogene Proteins - genetics
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This phase 2 trial assessed high-dose IV ascorbic acid in TET2 mutant clonal cytopenia. Eight of 10 patients were eligible for response assessment, with no responses at week 20 by International Working Group Myelodysplasia Syndromes/Neoplasms criteria. This trial was registered at www.clinicaltrials.gov as #NCT03418038.
ISSN:0006-4971
1528-0020
1528-0020
DOI:10.1182/blood.2024024962